ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Jeff, the most recent quarter reported an operating income of approx. $7 million. If they reach their 50% target,not guidance, but it is what they are targeting, it should give them a quarterly operating income of over $57 million. Most likely more, since this does not take into account the other products in the pipeline coming to market. A $240 million annual operating income is a possibility, 2019? 2020? We will probably have a better idea on potential launch dates once they have they Type C meeting with the FDA.

To put this into context for those new to ANIP, ANIP's operating income for 2016 was approx. $20 million.

Something else I am watching out for.

Abbvie is expected to file an NDA for Upadacitinib in 2018 and launch in 2019. It will be interesting to see if they use the PRV on this application. If not, then it furthers the possibility that it was intended for Libigel, when acquired. It wasn't used for the next generation HCV drug Mavyret or any of the other drugs that had been identified. It is basically down to Upadacitinib or an undisclosed drug not presently in their pipeline.


JMHO